Dianthus Therapeutics Inc. (DNTH NASDAQ) stock market data APIs
$17.5828
-0.56(-3.2%)
as of June 18, 2025
Try our APIs with
free plan!
Dianthus Therapeutics Inc. Financial Data Overview
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. The company's lead novel and proprietary monoclonal antibody product candidate includes DNTH103, a human monoclonal immunoglobulin G4 with picomolar that binds the active form of C1s, which is in clinical-stage trials for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.
Prev. Close
17.5828
Open
17.0205
High
18.0535
Low
16.9755
52 wk Range
13.365-32.27
Market Cap
561 M
Shares Outstanding
32 160 K
Revenue
6 524 K
EPS
-0.82
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Dianthus Therapeutics Inc. data using free add-ons & libraries
Get Dianthus Therapeutics Inc. Fundamental Data
Dianthus Therapeutics Inc. Fundamental data includes:
- Net Revenue: 6 524 K
- EBITDA: -117 096 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-07
- EPS/Forecast: -0.71
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Dianthus Therapeutics Inc. News
New
Climb Bio appoints Cindy Driscoll as SVP Finance and principal financial officer
Climb Bio, Inc. (NASDAQ:CLYM), a clinical-stage biotech company with a market capitalization of $81 million, announced the appointment of Cindy Driscoll as Senior Vice President, Finance, effective Ju...
Dianthus Therapeutics stock maintains buy rating ahead of September trial data
Stifel reiterated a buy rating and $52.00 price target on Dianthus Therapeutics (NASDAQ:DNTH), representing significant upside from the current price of $18.22. According to InvestingPro data, analyst...
Dianthus Therapeutics to Webcast Presentation at the Jefferies Global Healthcare Conference
NEW YORK and WALTHAM, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibod...
Dianthus Therapeutics Appoints Simon Read, Ph.D., to Board of Directors
Dr. Read brings >30 years of leadership and scientific expertise in the biopharmaceutical industry Previously served as CEO and Founder of Mariana Oncology until its acquisition by Novartis in 2024 a...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
